DeepSight Technology announced FDA 510(k) clearance for its NeedleVue LC1 ultrasound system. The milestone advances the company’s NeedleVue and OnPoint technologies for enhanced image-guided procedures. NeedleVue combines high-resolution ultrasound with intelligent instrument tracking for sub-millimetre accuracy. The system is designed to help clinicians target precisely, navigate complex anatomy and perform interventions with greater precision. Potential uses include biopsies, tumour ablation, targeted drug delivery, vascular access and structural heart repair. Other applications could extend to spinal therapies, neuromodulation, minimally invasive surgery and robotic-assisted procedures. The technology aims to lower procedural risk, reduce radiation exposure and shorten recovery times for patients. CEO Nader Sadrzadeh said the clearance represents a foundational step towards next-generation guidance inside the body. He stressed the system’s potential to improve visualization, procedural efficiency and user confidence. DeepSight plans to expand its clinical and commercial footprint in the coming months.